Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 8:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Agitation,Psychomotor Clear all
Completed Phase 3 Interventional Results available

A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's Agitation

NCT01862640
View directory record Official record
Conditions
Agitation Associated With, Alzheimer's Disease, Alzheimer's Type, Mental Disorder, Nervous System Diseases
Interventions
Brexpiprazole, OPC-34712, Placebo Oral Tablet
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 90 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Bellflower, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2020 · Synced Oct 5, 2026, 8:38 AM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial on Agitation in Alzheimer's Dementia

NCT05543681
View directory record Official record
Conditions
Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS, Aggression
Interventions
IGC-AD1-Active, IGC-AD1-Placebo
Drug
Lead sponsor
IGC Pharma, LLC
Industry
Eligibility
60 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Maitland, Florida • Melbourne, Florida • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02442765
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
111
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 78 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 5, 2026, 8:38 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 5, 2026, 8:38 AM EDT
Terminated Not applicable Interventional

Music Therapy is Associated With Decreased Pain and Agitation in Intubated ICU Patients

NCT01316536
View directory record Official record
Conditions
Music Therapy for Pain and Sedation
Interventions
provide headphones with music playing, Sounds
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 5, 2026, 8:38 AM EDT
Suspended Not applicable Interventional

ED-TREAT (Early Detection and Treatment to Reduce Events With Agitation Tool) Compared to Usual Care

NCT04959279
View directory record Official record
Conditions
Psychomotor Agitation, Behavioral Disorder
Interventions
ED-TREAT
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

NCT05557409
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
53
States / cities
Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Terminated Phase 3 Interventional Results available

An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study

NCT06736509
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
Interventions
AXS-05 (dextromethorphan-bupropion)
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
65 Years to 90 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Peoria, Arizona • Walnut Creek, California • Bonita Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Not applicable Interventional

Specific Interventions for Agitation in Alzheimer's Disease

NCT00018291
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Risperidone, Gabapentin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Not applicable Interventional

Decreasing Agitation in Patients With Dementia Through the Use of Weighted Blankets

NCT03643991
View directory record Official record
Conditions
Dementia
Interventions
Weighted Blanket
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

NCT03095066
View directory record Official record
Conditions
Neurobehavioral Disinhibition
Interventions
Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366
View directory record Official record
Conditions
Agitation
Interventions
Quetiapine, Haloperidol, Lorazepam, Cogentin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 26, 2019 · Synced Oct 5, 2026, 8:38 AM EDT
Completed No phase listed Observational

Helping Older Persons Emerge Stronger

NCT02863081
View directory record Official record
Conditions
Delirium, Ventilators, Pain, Agitation, Anxiety
Interventions
Survey, interview
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2017 · Synced Oct 5, 2026, 8:38 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease

NCT05477862
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Clinically Designed Improvisatory Music
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
55 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Prazosin for Agitation in Alzheimer's Disease

NCT03710642
View directory record Official record
Conditions
Alzheimer's Disease, Disruptive Behavior
Interventions
Prazosin, Placebo oral capsule
Drug
Lead sponsor
Alzheimer's Disease Cooperative Study (ADCS)
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
14
States / cities
Sun City, Arizona • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 5, 2026, 8:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Akathisia (Restless Legs Syndrome) in People With Schizophrenia and Mental Retardation

NCT00065286
View directory record Official record
Conditions
Akathisia
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 1999
U.S. locations
2
States / cities
Morganton, North Carolina • University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 8:38 AM EDT
Not yet recruiting Phase 2 Interventional

Inhibition of Aggressive Behavior in Participants With Fragile X Syndrome

NCT07328529
View directory record Official record
Conditions
Aggressive Behavior in Fragile X Syndome
Interventions
SRX246, Placebo
Drug
Lead sponsor
Azevan Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Sacramento, California • Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 4 Interventional Results available

Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)

NCT00385684
View directory record Official record
Conditions
Alzheimer Disease, Dementia, Dementia, Vascular, Pain
Interventions
hydrocodone/APAP w placebo PRN, hydrocodone/APAP, placebo with hydrocodone/APAP PRN
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
55 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 3 Interventional Results available

A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT03594123
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Brexpiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
55 Years to 91 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

Staccato Loxapine in Agitation (Proof of Concept)

NCT00369577
View directory record Official record
Conditions
Schizophrenia
Interventions
Inhaled Placebo, Inhaled Loxapine 5 mg, Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Upland, California
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 5, 2026, 8:38 AM EDT
Not listed Phase 1 Interventional

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT00197834
View directory record Official record
Conditions
Dementia
Interventions
Depakote
Drug
Lead sponsor
Hearthstone Alzheimer Care
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 15, 2006 · Synced Oct 5, 2026, 8:38 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Beyond Listening: A Music-based Intervention

NCT04840173
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Depressive Symptoms
Interventions
Music
Behavioral
Lead sponsor
MJHS Institute for Innovation in Palliative Care
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 3 Interventional

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

NCT05658510
View directory record Official record
Conditions
Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Bellflower, California • Cerritos, California • Culver City, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 5, 2026, 8:38 AM EDT
Completed Phase 2 Interventional Results available

DASH After TBI Study: Decreasing Adrenergic or Sympathetic Hyperactivity After Traumatic Brain Injury

NCT01322048
View directory record Official record
Conditions
Brain Injuries, Craniocerebral Trauma, Trauma, Nervous System, Traumatic Brain Injury
Interventions
IV Propranolol and Per Tube Clonidine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
16 Years to 64 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 5, 2026, 8:38 AM EDT